sotorasib is a small molecule inhibitor that explicitly targets the KRAS G12C mutation, a common mutation found in certain types of cancer, including NSCLC. The KRAS G12C mutation leads to uncontrolled cell growth and proliferation. sotorasib works by irreversibly binding to the mutant KRAS protein, inhibiting its signaling activity and interfering with downstream signaling pathways that promote tumor growth. By targeting this specific mutation, sotorasib aims to inhibit the cancer-promoting effects of KRAS G12C and slow down tumor growth.
Spectrum of Activity
sotorasib is specifically designed to target and inhibit the KRAS G12C mutation, predominantly found in non-small cell lung cancer (NSCLC). This mutation occurs in approximately 13% of NSCLC cases, making it the most common KRAS mutation in this cancer type. Therefore, sotorasib is primarily indicated for treating NSCLC patients with the KRAS G12C mutation.